(Circulation. 1999;99:1337-1343.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Molecular Heterogeneity in Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency Causing Pediatric Cardiomyopathy and Sudden Death
From the Departments of Pediatrics (A.M., H.F.S., B.G., A.W.S.), Medicine (D.G.), and Molecular Biology and Pharmacology (A.W.S.), Washington University School of Medicine and St Louis Children's Hospital, Mo; the Departments of Laboratory (P.R.) and Medical Genetics (J.V.), Mayo Clinic, Rochester, Minn; and the Department of Pediatrics, Cincinnati Children's Hospital and Medical Center (G.H.), Cincinnati, Ohio.
Correspondence to Arnold W. Strauss, MD, St. Louis Children's Hospital, One Children's Place, St Louis, MO 63110. E-mail strauss{at}kids.wustl.edu
Background—Genetic defects are being increasingly recognized in the etiology of primary cardiomyopathy (CM). Very-long-chain acyl-CoA dehydrogenase (VLCAD) catalyzes the first step in the ß-oxidation spiral of fatty acid metabolism, the crucial pathway for cardiac energy production.
Methods and Results—We studied 37 patients with CM, nonketotic hypoglycemia and hepatic dysfunction, skeletal myopathy, or sudden death in infancy with hepatic steatosis, features suggestive of fatty acid oxidation disorders. Single-stranded conformational variance was used to screen genomic DNA. DNA sequencing and mutational analysis revealed 21 different mutations on the VLCAD gene in 18 patients. Of the mutations, 80% were associated with CM. Severe CM in infancy was recognized in most patients (67%) at presentation. Hepatic dysfunction was common (33%). RNA blot analysis and VLCAD enzyme assays showed a severe reduction in VLCAD mRNA in patients with frame-shift or splice-site mutations and absent or severe reduction in enzyme activity in all.
Conclusions—Infantile CM is the most common clinical phenotype of VLCAD deficiency. Mutations in the human VLCAD gene are heterogeneous. Although mortality at presentation is high, both the metabolic disorder and cardiomyopathy are reversible.
Key Words: cardiomyopathy • death, sudden • fatty acids • genetics • metabolism
This article has been cited by other articles:
 |
|
 |
|
  F. ter Veld, S. Primassin, L. Hoffmann, E. Mayatepek, and U. Spiekerkoetter Corresponding increase in long-chain acyl-CoA and acylcarnitine after exercise in muscle from VLCAD mice J. Lipid Res., August 1, 2009; 50(8): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leatherbury, Q. Yu, B. Chatterjee, D. L. Walker, Z. Yu, X. Tian, and C. W. Lo A novel mouse model of X-linked cardiac hypertrophy Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2701 - H2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Werdich, F. Baudenbacher, I. Dzhura, L. H. Jeyakumar, P. J. Kannankeril, S. Fleischer, A. LeGrone, D. Milatovic, M. Aschner, A. W. Strauss, et al. Polymorphic ventricular tachycardia and abnormal Ca2+ handling in very-long-chain acyl-CoA dehydrogenase null mice Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2202 - H2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Exil, C. D. Gardner, J. N. Rottman, H. Sims, B. Bartelds, Z. Khuchua, R. Sindhal, G. Ni, and A. W. Strauss Abnormal mitochondrial bioenergetics and heart rate dysfunction in mice lacking very-long-chain acyl-CoA dehydrogenase Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1289 - H1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Exil, R. L. Roberts, H. Sims, J. E. McLaughlin, R. A. Malkin, C. D. Gardner, G. Ni, J. N. Rottman, and A. W. Strauss Very-Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency in Mice Circ. Res., September 5, 2003; 93(5): 448 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Klose, S. Kolker, B. Heinrich, V. Prietsch, E. Mayatepek, R. von Kries, and G. F. Hoffmann Incidence and Short-Term Outcome of Children With Symptomatic Presentation of Organic Acid and Fatty Acid Oxidation Disorders in Germany Pediatrics, December 1, 2002; 110(6): 1204 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V.i. G. Davila-Roman, G. Vedala, P. Herrero, L. de las Fuentes, J. G. Rogers, D. P. Kelly, and R. J. Gropler Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., July 17, 2002; 40(2): 271 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marin-Garcia and M. J. Goldenthal Fatty acid metabolism in cardiac failure: biochemical, genetic and cellular analysis Cardiovasc Res, June 1, 2002; 54(3): 516 - 527. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Cox, D. A. Hamm, D. S. Millington, D. Matern, J. Vockley, P. Rinaldo, C. A. Pinkert, W. J. Rhead, J. R. Lindsey, and P. A. Wood Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse Hum. Mol. Genet., September 1, 2001; 10(19): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Wood, M. J. Magera, P. Rinaldo, M. R. Seashore, A. W. Strauss, and A. Friedman Diagnosis of Very Long Chain Acyl-Dehydrogenase Deficiency From an Infant's Newborn Screening Card Pediatrics, July 1, 2001; 108(1): e19 - 19. [Abstract] [Full Text] [PDF]
|
|